Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below 50 Day Moving Average - Here's What Happened

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report)'s share price crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.91 and traded as low as $0.79. Seres Therapeutics shares last traded at $0.84, with a volume of 1,948,018 shares traded.

Wall Street Analyst Weigh In

A number of research analysts recently commented on MCRB shares. StockNews.com downgraded shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research report on Tuesday, August 13th. Chardan Capital reissued a "buy" rating and set a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, August 14th. Finally, Canaccord Genuity Group reissued a "buy" rating and set a $10.00 target price on shares of Seres Therapeutics in a research note on Friday, September 13th.

Seres Therapeutics Stock Performance

The business's 50 day simple moving average is $0.91 and its 200-day simple moving average is $0.91. The company has a market cap of $123.51 million, a price-to-earnings ratio of -1.36 and a beta of 2.03.

Seres Therapeutics (NASDAQ:MCRB - Get Free Report) last released its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.08. During the same quarter last year, the business posted $0.36 earnings per share. Research analysts expect that Seres Therapeutics, Inc. will post -0.95 earnings per share for the current year.

Insider Activity at Seres Therapeutics

In related news, insider Teresa L. Young sold 24,480 shares of Seres Therapeutics stock in a transaction on Monday, August 5th. The shares were sold at an average price of $1.08, for a total value of $26,438.40. Following the completion of the sale, the insider now owns 78,178 shares of the company's stock, valued at approximately $84,432.24. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last 90 days, insiders sold 28,844 shares of company stock valued at $30,104. Insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Seres Therapeutics in the 1st quarter valued at approximately $39,000. Providence Wealth Advisors LLC lifted its holdings in shares of Seres Therapeutics by 49.5% during the second quarter. Providence Wealth Advisors LLC now owns 76,250 shares of the biotechnology company's stock worth $58,000 after buying an additional 25,250 shares during the last quarter. Point72 DIFC Ltd acquired a new position in shares of Seres Therapeutics during the second quarter worth approximately $64,000. Virtu Financial LLC acquired a new position in shares of Seres Therapeutics during the first quarter worth approximately $73,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Seres Therapeutics during the second quarter worth approximately $92,000. Institutional investors own 59.34% of the company's stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.